Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuAdoptive immunotherapy for cancer: building on successT cell avidity and tumor recognition: implications and therapeutic strategies.Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy.A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.Recombinant antibodies for cancer diagnosis and therapy.TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.Long wavelength fluorophores and cell-by-cell correction for autofluorescence significantly improves the accuracy of flow cytometric energy transfer measurements on a dual-laser benchtop flow cytometer.Changing T cell specificity by retroviral T cell receptor display.Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Engineered T cells for cancer treatmentRedirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes.Targeting tumours with genetically enhanced T lymphocytes.Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.Facilitating matched pairing and expression of TCR chains introduced into human T cells.Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.Engineering T cells for cancer therapy.Supernatural T cells: genetic modification of T cells for cancer therapy.Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.T-cell receptor gene therapy for cancer: the progress to date and future objectives.An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.Treatment of lymphoma with adoptively transferred T cells.Enhanced T cell receptor gene therapy for cancer.Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacitiesApplication of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells.TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity.Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX.Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function.Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
P2860
Q21131200-CB4CA45B-3C5D-44D7-92E4-0474CA6A3246Q24546258-C0D08120-D441-4491-A1B3-FD8BC6D0E72EQ24815775-F09F4265-86FA-4BC4-AFA2-E0311A2FBDA0Q30446191-9C85062A-D1B8-4C38-AC8E-E60E71E28C6FQ30700012-68FFF59E-8306-44A2-B1D4-8500C5117A8AQ30771917-19220A73-9EC2-4974-AB32-44FAB6BEAFBBQ30831500-AF9D231E-030A-4F2D-A3EC-255199A4532FQ30836566-946FF2FB-DDC1-4548-9885-0797356115FEQ30976853-B9B837C6-C0A6-4808-9269-3D04FF5A3AB9Q33183860-CDBCDA71-FF26-4CF6-B3DB-99632190FB4EQ33208099-DB8C7736-A934-4136-9C2D-D2CF8176C238Q33368725-96741480-3975-46D3-A49A-3878794BF3B5Q33530527-8E20CAD8-505A-40CC-902E-DEBC5851E6B4Q33578792-975368CC-045B-4366-A3C4-C49300A855C8Q34602524-96982097-C91A-4D9B-A3FB-12C98F44478DQ35037678-F43FFBB5-56C8-4063-8938-E71F1ED17492Q35160569-D93C9C9C-7472-416A-B7E5-C06AAADC1CF4Q35221732-CBED5584-A489-4AE2-86B2-05AB7BB3172DQ35650970-1BA1659D-D9F2-4690-BECF-4981F7F2F39FQ35750844-8EB25542-01BA-4995-9DA9-664A43C8B6E2Q36286127-B01E2A11-6E13-4114-AA64-3D3DDDB6D6FBQ36298319-EA2BD4DC-61B7-40B1-9391-C81E9D1893D4Q36328805-1757BBEB-136C-42A4-B4B8-BD5DAE37460BQ36453570-D7AD4A98-021A-43A0-8C32-3396E375D438Q36471584-07A5D6E7-404B-44FB-BBDE-54C9725E98E1Q36883838-2170DD81-08A7-4113-8D60-2720C4D75C4FQ36909378-94D1D433-91EA-4E21-8C72-FD53F77A2FFBQ37225251-F1584CBE-FD33-492D-934A-B4A7A2709A44Q37419728-3B5F433A-E591-44AD-9C0F-C81FBCD855EEQ37702226-26879E45-ABEC-4033-91F8-5F3F64B64871Q37741606-74C8BAE2-DDB9-488B-9178-2DE683982379Q37747066-33B3B7CB-64F8-48B0-B273-133DE3FC7BF0Q37854072-61DF25EF-3D88-4185-A2D3-2B18425A85EBQ39374243-A9F0FC38-B926-4A1C-B897-3A024818E330Q39383424-3EEABE7D-519D-475F-9419-4133CF3CFD3AQ39507137-33BE5BA9-AE80-4EE1-8465-5A3D9F4F991AQ39833455-93113B8C-BA89-4FED-AF4E-DAC08A636313Q40005191-9E697FE8-F33C-4513-A520-DA36AECA7B90Q40553796-27A10C95-71BB-4145-87A9-2D9FF469A215Q40619033-8575B449-9BFB-43CC-B561-F0FC91105057
P2860
Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Grafting primary human T lymph ...... ingle chain and two chain TCR.
@ast
Grafting primary human T lymph ...... ingle chain and two chain TCR.
@en
type
label
Grafting primary human T lymph ...... ingle chain and two chain TCR.
@ast
Grafting primary human T lymph ...... ingle chain and two chain TCR.
@en
prefLabel
Grafting primary human T lymph ...... ingle chain and two chain TCR.
@ast
Grafting primary human T lymph ...... ingle chain and two chain TCR.
@en
P2093
P2860
P356
P1433
P1476
Grafting primary human T lymph ...... single chain and two chain TCR
@en
P2093
Bolhuis RL
Gratama JW
Ronteltap C
Weijtens ME
Willemsen RA
P2860
P2888
P304
P356
10.1038/SJ.GT.3301253
P577
2000-08-01T00:00:00Z